A clinical trial included people (without diabetes) with common obesity and people with one of the most common monogenic causes of obesity in humans, a mutation in the melanocortin‐4 receptor (MC4R).(44) They observed a 6% weight loss in both groups but no differences in markers of bone turnover (CTX, osteocalcin and P1NP) after 16 weeks of liraglutide treatment (neither in groups of between groups). Here, MC4R is linked to diabetes mellitus.